Stockreport

EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarket [Seeking Alpha]

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com
PDF EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarketRigel Pharmaceuticals (NASDAQ:RIGL) is up2% premarket on li [Read more]